MN-DIGI-INTERNATIONAL
21.6.2022 09:02:08 CEST | Business Wire | Press release
Digi International, (NASDAQ: DGII, www.digi.com ), a leading global provider of Internet of Things (IoT) solutions, connectivity products and services, today extended its IoT solution portfolio with the unveiling of its new Digi ConnectCore® MP1 family of system-on-modules (SOMs). The MP1 is the industry’s smallest STM32MP1 SOM that integrates Wi-Fi, Bluetooth and wired connectivity without comprising design flexibility.
This solution is made complete with its Connected Device platform as well as its well-tested development tools and design support. This makes Digi ConnectCore MP1 SOMs a cost-effective wireless solution for original equipment manufacturers (OEMs) seeking to reduce risk and effort in their product development. Ideal Digi ConnectCore MP1 applications include handheld products with cameras and/or displays such as medical devices, environmental test equipment, industrial human machine interfaces, or headless devices such as EV charging stations, renewable-energy controllers and others.
Leveraging both new and market-proven STM32MP1 micro processing units (MPUs) from STMicroelectronics (STM), Digi ConnectCore MP1 SOMs offer more features with a lower total cost of ownership. The form factor is smaller than a postage stamp (29x29 mm), which is ideal for form-factor-challenged applications with low-profile requirements. These off-the-shelf family of Digi ConnectCore MP1 SOMs bring scalability, compatibility and pre-certified wireless connectivity in a solution suitable for a broad range of applications in the healthcare, transportation and industrial sectors.
The unique Digi SMTplus™ surface-mount form factor provides design flexibility by enabling more complex applications through land grid array (LGA) pads and less complex applications using edge-castellated pads. By eliminating the need for connectors, ConnectCore SOMs shrink the bill of materials and offer greater suitability for high-vibration and harsh environment applications where connectors are prohibitive.
Small Form Factor Packed with High-Performance Features
- STM32MP15x, single/dual Cortex-A7 @ 650 MHz
- Cortex-M4 companion processing core for real-time tasks (STM32MP15x only)
- Pre-certified Wi-Fi 5 802.11a/b/g/n/ac + Bluetooth 5.0 (including DLE) option
- Up to 1 GB SLC NAND flash, up to 1 GB DDR3
- Unique ultra-low power and wake-up state management
- Dual 10/100/1000 Ethernet connectivity (single 10/100/1000 Eth for STM32MP15x)
- Fully validated embedded Linux software platform (Digi Embedded Yocto)
- Digi TrustFence® embedded security framework – ready-to-use security features
- Off-the-shelf development board and low-cost gateway reference design
- Industrial reliability and operating temperature with leading hardware warranty
“Digi ConnectCore MP1 SOMs respond to the challenge of building intelligent, connected and secure wireless products in strongly regulated markets such as the healthcare, transportation, and industrial sectors,” said Andreas Burghart, Senior Product Manager with Digi. “Unlike other SOMs, Digi ConnectCore MP1 provides a scalable, highly integrated solution that encompasses a complete set of development tools, design support, software, and security building blocks to accelerate time to market. Digi also provides remote management and security services to simplify deployment and ongoing maintenance throughout the entire product lifecycle.”
For more information, visit https://www.digi.com/ccmp1 .
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005044/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom